Replication-selective oncolytic adenoviruses hold promise, but novel mechanisms must be identified to maximize intratumoral virus persistence, spread and therapeutic transgene-carrying capacity while maintaining safety. One of the main approaches to engineering cancer-selectivity has been to delete a viral gene that is theoretically expendable in cancer cells. Results with this approach have been mixed, however, as evidenced by controversy over Onyx-015 (E1B-55kD(À)) selectivity. We hypothesized that the functional redundancy between viral gene products might limit selectivity and/or potency with this approach. Antiviral immune inducers of apoptosis (eg TNF-a) have not been thoroughly investigated in previous studies. We therefore explored whether deletion of functionally redundant viral genes, E1B-19kD and E3B, both independently antagonize TNF-a, could lead to enhanced oncolytic potency while maintaining selectivity. Since tumors have numerous blocks in apoptotic pathways, we hypothesized that deletion of one or both gene regions would result in cancer-selectivity in the presence of TNF-a. We have previously shown that the E1B-19kD deletion resulted in enhanced viral spread in vitro and in immunocompetent tumor models in vivo. In contrast, the impact of E3B deletion, especially its in vitro selectivity and potency, was not thoroughly characterized, although it resulted in rapid immune-mediated viral clearance in vivo. Furthermore, previous publications indicated that doubledeleted mutants have selectivity but unsatisfactory efficacy. We compared the selectivity and potency of E1B-19kD(À), E3B(À) and E1B-19kD(À)/E3B(À) mutants to wild-type adenovirus. In cancer cells, the E1B-19kD(À) mutant had superior replication, spread and cytolysis (+) or (À) TNF-a; deletion of both E1B-19kD and E3B was relatively deleterious. In normal cells without TNF-a, similar results were obtained. In contrast, all three mutants were significantly inhibited in the presence of TNF-a. In immunocompetent mice, all three mutants were significantly inhibited in normal tissue. In tumors, only the E1B-19kD(À) mutant demonstrated enhanced replication, spread and antitumoral efficacy. Therefore, E1B-19kD deletion and E3B retention should be incorporated in oncolytic adenoviruses for enhanced safety and efficacy. In addition, functional redundant viral genes and their biological mediators/targets need to be carefully examined for the next generation of gene-deleted oncolytic viruses.
Introduction
Oncolytic viruses have been developed as a new platform for cancer therapy.
1,2 These replication-selective viruses have a high therapeutic index relative to many standard chemotherapeutic agents. The cancer-selective self-amplifying nature of these viruses means that a small 'input' dose can result in therapeutic index enhancement over time. Moreover, these viruses can be engineered to destroy tumors through numerous mechanisms, including the coexpression of exogenous therapeutic genes. 3 The development of treatment-resistance should therefore be antagonized. Two general approaches are most commonly used to achieve selectivity for oncolytic adenoviruses: transcriptional control of critical viral genes with tumor/ tissue-specific promoter/enhancer elements and viral gene deletions. The gene deletion approach takes advantage of the evolutionary convergence between the processes of carcinogenesis and adenoviral replication. Since many of the same cellular functions are inactivated during both processes, viral genes can be identified that are necessary for replication in normal cells but expendable in cancer cells. Cancer-selective deletion mutants include dl922-947 and dl1520 (a.k.a. Onyx-015). Unfortunately, this approach can result in a loss of anticancer potency; for example, dl1520 (Onyx-015) was attenuated versus wild-type adenovirus in most cancer cells. 4 It is therefore not surprising that in clinical trials with Onyx-015 tumor responses were rare as a single agent (p10%). 1 In addition, rapid clearance of the adenoviruses by the host immune system also contributes to the low efficacy. 5 The lack of long-term persistence in tumors prevents further oncolysis and antitumoral response. Several publications have also indicated that the selectivity of Onyx-015 is not completely p53-dependent; the status of p14 ARF , rather than p53, seems to play an important role. 6 It is therefore critical that new oncolytic adenoviruses maintain selectivity but have enhanced potency. In addition to improving the efficacy of the 'base' virus backbone itself, 'arming' these viruses with exogenous therapeutic genes will be a highly attractive approach. Since space in the adenovirus genome is limited, 7 it will be critical to identify genes that can be deleted without adversely affecting the therapeutic index while allowing additional genetic material to be inserted. Therefore, the identification of novel adenoviral gene deletions was eagerly awaited. We hypothesized that the functional redundancy of viral gene products might limit the selectivity and potency of oncolytic adenovirus and therefore enhanced selectivity and potency can be achieved through systemic exploration of redundant viral genes.
Adenoviruses express antiapoptotic proteins with different mechanisms of action to prevent premature apoptosis and virus replication shut-off. Tumor necrosis factor (TNF-a) is a major antiadenovirus cytokine. [8] [9] [10] As a result, adenovirus encodes for several proteins that antagonize the cell death effects of TNF-a, specifically E1B-19kD, E3-10.4/14.5kD and E3-14.7kD. As a Bcl-2 functional homologue, E1B-19kD is able to inhibit apoptosis by interrupting FADD oligomerization and by binding to Bax and Bak. 11, 12 E1B-19kD appears capable of inhibiting apoptosis from both receptormediated death signaling pathways and via the mitochondrial pathway. 13 In addition, E1B-19kD is also able to indirectly counteract the function of the E3 protein ADP in preventing premature viral release. 14 The adenovirus E3B region encodes the E3-10.4/14.5kD (RID complex) and E3-14.7kD. The RID complex, which localizes to the plasma membrane, Golgi and ER, can internalize and degrade Fas, EGFR and TRAIL-R1 from cell surface, blocks TNF-induced release of arachidonic acid and translocation of cytosolic phospholipase A2 to membranes. [15] [16] [17] E3-14.7kD , in contrast, is a cytoplasmic protein that can inhibit TNF-, Fas-and TRAIL-induced apoptosis independent of the RID complex. 18, 19 Therefore, E3B and E1B-19kD protect against TNF-induced apoptosis through different mechanisms. Cancer cells have numerous blocks in apoptotic pathways, including those triggered by TNF-binding. [20] [21] [22] We hypothesized that adenovirus mutants with deletions in one or both of these gene regions would be cancer-selective in the presence of TNF due to premature apoptosis in normal cells but not in cancer cells. The impact of another antiapoptotic gene, E1B-55kD, is not examined, since previous publications have indicated that deletion of this gene region, either in isolation or in the context of a complete E1B deletion, significantly reduced potency and viral yield, 23, 24 although it must also be pointed out that mutant viruses described in these papers included deletions in E3 region, and interactions between these different genes in isolation were not studied in detail.
We have recently shown that E1B-19kD deletion enhances viral replication and spread, in addition to augmenting TNF-associated selectivity. 25 On the other hand, although most currently available oncolytic adenoviruses contain E3B deletions, [26] [27] [28] the effect of this gene deletion in isolation on oncolytic potential has not been described. Functional interactions between these viral proteins in the context of an oncolytic adenovirus also remain poorly understood. Previous publications showed that double deletion of E1B-19kD and E3B resulted in enhanced release, higher apoptosis induction and similar replication efficiency compared to its E3B-deleted control. 29, 30 These results are of clear interest. However, several critical questions remained unanswered. First, these gene deletions were not evaluated in isolation. In addition, the effects of these gene deletions, in isolation or combination, were not explored in normal cells in vitro or in vivo. The role of TNF-a was not investigated in these studies. Although in vivo efficacy studies were performed in athymic mice with one tumor cell line, the relative antitumoral efficacy of the single or combination gene mutants versus the wild-type control was not evaluated. Finally, the impact of a fully intact host immune system on these mutants had not been explored. Thus, this work represents a conceptual advance regarding deletion(s) of potentially redundant genes and implications for oncolytic virotherapy. In this report we describe for the first time the relative oncolytic potency and selectivity of E1B-19kD(À), E3B(À) and E1B-19kD(À)/E3B(À) mutants compared to wild-type adenovirus in vitro and in vivo. Of note, the roles of TNF and an intact immune response were determined. To accomplish this we took advantage of a novel immunocompetent tumor model that we recently described in which intratumoral adenovirus replication occurs 31 and the fact that murine liver is semipermissive for human adenovirus replication. 32 
Results
Adenoviral E1B-19kD-and E3B-deletions enhance viral replication in tumor cells at relatively early or late time-points, respectively
In order to study the impact of the E1B-19kD, E3B and E1B-19kD/E3B deletions on viral replication, the titer of each virus was compared with their relevant wildtype control (ie dl250/Ad2wt, dl309/Ad5wt and dl337/ Ad5wt) over time. We first compared the replication time course of wild-type adenovirus (Adwt; Ad2 and Ad5), the E1B-19kD-deletion mutant dl250 (Ad-E1B-19kD(À)), the E3B-deletion mutant dl309 (Ad-E3B(À)), and the E1B-19kD/E3B double deletion mutant dl337 (Ad-E1B-19kD(À)/E3B(À)). Viral yield of Adwt ranged from 1.6 Â 10 7 to 1. 6 PFU/ml in murine tumor lines at 72 h p.i. In all human tumor cell lines, the mutant viruses replicated at or above the level of the Adwt at both time-points (Figure 1a -c; presented as % of Adwt). Ad-E1B-19kD(À) titers were highest relative to Adwt at 48 h p.i. (300-1800% of wild type; Po0.05), although titers were still greater than for Adwt at 72 h p.i. also (130-950%). Ad-E3B(À) also replicated better than Adwt in human tumor cells, but its highest levels relative to Adwt were seen at 72 h (250-500% of wild type; Po0.05). Overall, Ad-E1B-19kD(À) demonstrated significantly accelerated replication relative to both Oncolytic adenovirus E1B-19kD, E3B and E1B-19kD/E3B deletion mutants T-C Liu et al Ad-E3B(À) and Adwt at 48 h in human tumor cells (Po0.05). Deletion of both gene regions appeared to be deleterious. At neither time-point was the Ad-E1B-19kD(À)/E3B(À) mutant able to replicate to a relative titer as high as the best replicating single deletion mutant (Figure 1a-c) . We have recently identified murine tumor cells that support low level replication of human adenovirus; 31 these include JC and CMT-167 cells. As was demonstrated in human tumor lines, Ad-E1B-19kD(À) enhanced replication versus Adwt (Figure 1d and e; 200-800% of wild type; Po0.05 for 72 h), but the effects were delayed relative to human tumor lines; this is consistent with the delayed replication time course seen in murine tumor cells. 31 The E3B(À) and double deletion mutants also replicated to levels above Adwt (200-300%; Po0.05) in JC cells at both time-points but not in CMT-167 cells (P40.05). At 72 h, Ad-E1B-19kD(À) titer was significantly higher than for the other mutant viruses in CMT-167 cells (Figure 1e ; 800% of wild type, Po0.05).
Replication in normal cells is reduced by E3B-deletion but not E1B-19kD deletion in the absence of TNF-a
In human normal cells (NHBE), only Ad-E1B-19kD(À) had significantly higher titers compared to Adwt (Figure   1f ; Po0.05 at 48 h). In contrast, both Ad-E3B(À) and Ad-E1B-19kD(À)/E3B(À) replicated less efficiently than Adwt in these normal cells (60 and 40% of Adwt at 72 h, respectively; Po0.05); titers of the double deletion mutant were lower than for either of the single deletion viruses.
Taken together, E1B-19kD deletion significantly enhanced viral replication in both tumor and normal cells, particularly at relatively early time-points following infection. In tumor cells, E3B-deletion also resulted in enhanced viral replication relative to Adwt; however, this effect was less pronounced than with the E1B-19kD deletion, and it occurred primarily at later time-points. The double deletion appeared to be deleterious in tumor cells. In normal cells, in contrast, both the E3B-deletion and double deletion mutants demonstrated significant attenuation relative to Adwt. (Figure 2a, c ; 1800-2200% of wild type; Po0.05), and titers were still greater than Adwt at 72 h (Figure 2a-c ; 400-4800% of wild type). Overall, Ad-E1B-19kD(À) demonstrated significantly accelerated viral release relative to both Ad-E3B(À) and Adwt at 48 and 72 h in tumor cells (Po0.05). Deletion of both gene regions appeared to be deleterious. With the exception of A2780, at neither time-point was Ad-E1B-19kD(À)/ E3B(À) able to release to a relative titer as high as Ad-E1B-19kD(À) (Figure 2a-c) . As was demonstrated in human tumor lines, Ad-E1B-19kD(À) mutant enhanced viral release versus Adwt in murine cells (Figure 2d ; 300-1300% of wild type; Po0.05 at 72 h), but the effects were delayed relative to human tumor lines; this is consistent with the delayed replication time course shown above. As seen in human tumor cells, A2780 and A2780/CP, Ad-E3B(À) and Ad-E1B-19kD(À)/E3B(À) did not show enhanced viral release over Adwt. At 72 h, Ad-E1B-19kD(À) titer was significantly higher than for the other mutant viruses (Figure 2d ; 1300-1500% of wild type, Po0.05).
Similar findings were obtained following infection of normal (NHBE) cells. Only Ad-E1B-19kD(À) had significantly higher titers in media compared to Adwt (Figure 2e ; Po0.05). In contrast, Ad-E3B(À) did not show significantly enhanced viral release. Ad-E1B-19kD(À)/ E3B(À) also showed enhanced viral release compared to both Adwt and Ad-E3B(À) (Po0.05).
Taken together, E1B-19kD deletion significantly enhanced viral release in both tumor and normal cells, particularly at relatively early time-points following infection. E3B-deletion had no effect on viral release. The double deletion appeared to be deleterious in most tumor cells as well as in normal cells. In human normal (NHBE) cells, all mutant viruses were more potent than wild-type control. However, Ad-E1B-19kD(À)/E3B(À) had the highest EC 50 value ratio to Adwt whereas Ad-E1B-19kD(À) mutant had the lowest EC 50 value ratio to Adwt.
TNF-a inhibits replication of E1B-19kD(À) and E3B(À) adenoviruses in normal cells through apoptosis induction
We hypothesized that the TNF-a protection effect of E1B-19kD and E3B might be more significant in normal cells, which possess intact apoptosis pathways, than in tumor cells which have multiple genetic blocks in apoptosis pathways. We therefore explored the impact of E1B-19kD and E3B gene deletions on viral replication, viral release and apoptosis induction in the presence of TNF-a. Tumor cell lines PT45, CMT-167, JC and normal NHBE cells were infected with viruses, and TNF-a (0.5 ng/ml) was added to the culture media at 6 h p.i. Of note, no significant change in survival was seen in these cells when treated with TNF-a alone (dose ranging from 0.001 to 1000 ng/ml; data not shown); in addition, previous clinical trials and in vivo studies have shown that peak TNF-a levels after intravascular adenovirus delivery were between 0.03 and 6.5 ng/ ml. [33] [34] [35] [36] At 48 and 72 h p.i., samples were harvested and titered as described. Mutant viruses were still associated with enhanced viral replication compared to Adwt in PT45 cancer cells (Figure 4c, d ). Of note, the quantity of these viruses produced did not change in the presence of TNF-a. Similar results were found in murine tumor cells (data not shown). TNF-a therefore had no demonstrable effect on viral replication in these tumor cells.
In contrast, in normal cells, the replication of the mutant viruses, but not of Adwt, was significantly reduced in the presence of TNF-a. Although at 48 h p.i. the titers of mutant viruses in normal NHBE cells in the presence of TNF-a were similar to that obtained without TNF-a treatment (Figure 4a ), by 72 h p.i. all mutant viruses had significantly reduced titers after TNF-a treatment (Figure 4b ; Po0.05 for all mutant viruses versus Adwt). Of note, Ad-E1B-19kD(À) had the greatest degree of viral titer reduction (Po0.05 versus Ad-E3B(À) and Ad-E1B-19kD(À)/E3B(À)). Ad-E3B(À) titer decreased from 60 to 40% of Adwt, and Ad-E1B-19kD(À)/E3B(À) titer decreased from 40 to 20% of Adwt, whereas Ad-E1B-19kD(À) decreased from 180 to 60% of Adwt. In addition, in the presence of TNF-a, the absolute titer of Ad-E1B-19kD(À) at 72 h p.i. was actually lower than that at 48 h p.i. (Po0.05); this finding suggests inactivation of Ad-E1B-19kD(À) by TNF-a. These data demonstrate that E1B-19kD is more efficient in protecting these NHBE cells from TNF-a than E3B, but that both gene regions play a role.
Virus release into the culture media followed a similar trend. In cancer cells, the titer of each virus in the culture media remained similar with and without TNF-a treatment (data not shown). In NHBE, no significant change was found in the released virus titer of Adwt and Ad-E3B(À) with and without TNF-a treatment. In contrast, the titer of both Ad-E1B-19kD(À) and Ad-E1B-19kD(À)/E3B(À) showed a 45-50% reduction in viral release from normal NHBE cells in the presence of TNF-a (Po0.05; data not shown).
We hypothesized that mutant virus replication inhibition and virus inactivation in normal cells was due to TNF-induced apoptosis. To assess this mechanism, the EC 50 values for these viruses were determined with and without TNF-a added at 6 h p.i. The EC 50 value for Adwt did not significantly change in any of these cell lines after TNF-a treatment (data not shown). Likewise, the EC 50 value for mutant viruses in the tumor cell lines did not significantly change in the presence of TNF-a (Figure 4e ). In contrast, the EC 50 value for both Ad-E1B-19kD(À) and Ad-E1B-19kD(À)/E3B(À) in NHBE showed a 20% decrease (Po0.05). On the other hand, the EC 50 value for the Ad-E3B(À) in NHBE showed an 11% decrease. Therefore, although all mutant viruses-infected NHBE cells were sensitized to TNF-a, E1B-19kD seems to be more efficient in protecting these cells than E3B.
Apoptosis induction was also assessed by in situ caspase-3 active form in normal cells (NHBE) and cancer cells (PT45). At 24 h p.i., neither TNF-a nor Adwt treatment alone significantly increased the apoptotic fraction in normal (NHBE) cells (Figure 4f ; TNF-a or Adwt versus mock: P40.05). Ad-E3B(À) induced a higher apoptotic fraction (21 versus 37%; mock versus dl309: Po0.05), whereas Ad-E1B-19kD(À) induced an even higher apoptotic fraction (21 versus 47%; mock or Adwt versus dl250: Po0.01), as did the double deletion mutant (21 versus 46%; mock or Adwt versus dl337: Po0.01). When TNF-a was added after viral infection, although no significant increase in apoptotic fraction was found in mock-or Adwt-infected cells, the apoptotic fraction of Ad-E1B-19kD(À)-infected cells increased to 57% (Po0.05), and Ad-E3B(À)-infected cells increased to 46%. Ad-E1B-19kD(À)/E3B(À)-infected cells increased to 63% (Po0.01). Therefore, the decrease in viral Oncolytic adenovirus E1B-19kD, E3B and E1B-19kD/E3B deletion mutants T-C Liu et al replication and titers after TNF-a treatment in mutant viruses-infected NHBE correlated with rapid and efficient induction of apoptosis. In contrast, no significant differences between virus and virus+TNF-a treatment groups were demonstrated in tumor cells (data not shown).
In addition, from the data gathered above, whereas E3B deletion in isolation only modestly increased the sensitivity of normal cells to TNF-a, E1B-19kD deletion in isolation had a highly significant effect. Deleting both E1B-19kD and E3B, however, did not significantly increase the apoptosis rate compared to E1B-19kD (e) EC 50 ratio (+/À TNF); Open bars: dl250/Ad2wt; filled bars: dl309/Ad5wt; gray bars: dl337/Ad5wt. (f) In situ caspase-3 activation was determined as an indication of apoptosis induction. NHBE cells were untreated or treated with viruses and/or TNF-a as described. At 24 h postinfection, cells were fixed and stained for active form caspase-3 as mentioned (n ¼ 4). *, TNF-a treatment.
Oncolytic In summary, these in vitro data suggest that the mechanism of cell death in normal cells is mainly through apoptosis induction, especially when the death signal TNF-a is present, while in cancer cells it is through replication and oncolysis.
In vivo viral gene expression, replication and cytopathic effects in normal tissues are decreased significantly by E1B-19kD and/or E3B deletion
The results shown above indicated that the selectivity of these mutant adenoviruses might be enhanced in vivo, especially in animals with an intact immune system. We therefore tested these viruses on immunocompetent tumor-bearing mice, which allowed us to compare the replication status of these viruses in tumors in vivo. Since the majority of intravenously injected virus is cleared by the liver, 37 we compared the virus replication and pathology in both liver and tumor tissues. Of note, murine liver is semipermissive for adenoviral replication. 32 Ad-E1B-19kD(À) mutant expressed its genes and appeared to replicate at levels similar to Adwt at 24 h postinjection, as expected, but by 48 h was significantly reduced compared to Adwt (Figure 5a ; P-value between 24 and 48 h o0.05). This is consistent with the in vitro data described above; Ad-E1B-19kD(À) showed enhanced viral replication in normal cells at very early time-points, but had significantly reduced replication and titers at later time-points in the presence of TNF-a. Also, consistent with previous findings, Ad-E3B(À) expressed its genes and replicated at a significantly lower level than Adwt in normal livers at both timepoints. With Ad-E1B-19kD(À)/E3B(À), the viral gene expression in livers was even less than that with either of single deletion mutants. These results were confirmed by PFU recovery from livers. At 24 h postinjection, the titer of Ad-E1B-19kD(À) was 170% of Adwt, Ad-E3B(À) was 120% of Adwt and Ad-E1B-19kD(À)/E3B(À) was 40% of Adwt ( Figure 5b) . However, at 48 h postinjection, whereas the titer of Adwt continued to increase, the titers of mutant viruses were decreased significantly. The titer of the mutant (as compared to Adwt) was 20% for Ad-E1B-19kD(À), 6% for Ad-E3B(À) and 2% for Ad-E1B-19kD(À)/E3B(À).
The severity of CPE induced in virus-exposed liver tissues was scored and compared as described before in blinded fashion. 31 In C57BL/6 mice bearing CMT-167 tumors, the CPE severity in livers following mutant virus treatment did not increase throughout 48 h post-treatment, while the CPE severity in Adwt-treated mice increased significantly between 24 and 48 h post-treatment (data not shown). Of note, the CPE severity in Adwt-treated livers was consistently higher than mutant viruses-treated livers throughout 48 h post-treatment (Figure 5c ; P-values between Adwt and mutants at 48 h o0.05). In addition, Adwt-exposed livers had more severe periportal inflammation than both Ad-E1B-19kD(À) and Ad-E1B-19kD(À)/E3B(À) mutants-exposed livers (Figure 5d Interestingly, E3B-deletion in isolation was associated with greater inflammation as was previously described. 31 Liver function tests also showed that the Adwt treatment group had significantly higher AST and ALT levels than the mutant virus treatment groups (Figure 5e ). Figure 5g represents an example of the pathology of liver samples harvested at 24 h post-treatment. In Balb/c mice, Adwt also induced more severe liver damage than did the mutants (data not shown). Thus, the decreased hepatotoxicity of the mutants was associated with reduced viral replication/persistence in two murine species and confirmed the in vitro findings.
Finally, caspase-3 activity was evaluated over time post-treatment in both liver and tumor tissues. Ad-E1B-19kD(À)-exposed livers showed significantly higher apoptosis scores at early time-points (24 h), as expected. The level was quickly decreased to a level less than Adwt at 48 h (Figure 5f ). Ad-E3B(À)-exposed livers had similar apoptosis scores to Adwt-exposed livers, and Ad-E1B-19kD(À)/E3B(À)-exposed livers had lower scores. These data suggest that apoptosis plays a greater role in the clearance of the E1B-19kD deletion mutant from normal tissues than for the E3B mutant; this finding is consistent with in vitro data.
In vivo viral gene expression and replication in tumor tissues are increased significantly by E1B-19kD deletion
Intratumoral viral gene expression and titers were compared by intratumoral injection of the viruses into murine JC tumors in immunocompetent mice. At 6 days postinjection, whereas the Adwt and Ad-E3B(À) treatment groups showed equivalent E1A expression, the Ad-E1B-19kD(À)/E3B(À) treatment group showed 1.5-fold higher E1A expression (Figure 6a ). In contrast, the Ad-E1B-19kD(À) treatment group showed five-fold higher E1A expression. Similar trend was seen on day 10 (data not shown). The infectious PFU recovery from tumor samples at similar timepoints showed similar and highly significant differences. At 6 days post-treatment, whereas Ad-E3B(À) treatment group showed 0.6-fold PFU relative to Adwt, Ad-E1B-19kD(À)/E3B(À) treatment group showed 16-fold higher viral PFU/gm tumor, and the Ad-E1B-19kD(À) treatment group showed 1800-fold higher titer than Adwt (Figure 6b ; Po0.01). Taken together, Ad-E1B-19kD(À) mutant was associated with the greatest PFU ratio of any of the mutant viruses. In addition, Ad-E1B-19kD(À)/E3B(À) showed greater viral replication than the Ad-E3B(À) in tumors.
The superior intratumoral replication of Ad-E1B-19kD(À) was also confirmed in a second immunocompetent murine tumor model and by the intravenous route of injection. Immunocompetent C57BL/6 mice bearing CMT-167 murine tumors received viruses via tail vein as described. At 24 and 48 h postinjection, adenoviral gene expression and PFU titers were assessed in tumors. Ad-E1B-19kD(À) was associated with significantly higher numbers of hexon-expressing cells (Figure 6c ; 1100-and 400-fold higher than Adwt at 24 and 48 h postinjection, respectively; Po0.01). The PFU titer data was similar; the infectious PFU titers within the tumors in the Ad-E1B-19kD(À)-treated group were 170-and 1100-fold higher than Adwt at 24 and 48 h postinjection, respectively (Figure 6d ; Po0.01).
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Antitumoral efficacy of the E1B-19kD mutant in vivo
Two human tumor xenograft models were used to compare the in vivo efficacy of the viruses. We first tested the efficacy of these viruses in an orthotopic human breast cancer MDA-MB-231 xenograft model. The Ad-E1B-19kD(À) treatment group showed superior Oncolytic adenovirus E1B-19kD, E3B and E1B-19kD/E3B deletion mutants T-C Liu et al efficacy against all other virus treatment groups in this model. At 96 days post-treatment, 75% of the animals treated with Ad-E1B-19kD(À) survived, whereas no animals survived in other treatment groups ( Figure 7) . Therefore, Ad-E1B-19kD(À) was associated with superior efficacy compared to Adwt, Ad-E3B(À), or Ad-E1B-19kD(À)/E3B(À) mutants in a human tumor xenograft model of intravenous treatment. As expected, dl1520 efficacy was significantly worse than with Adwt or Ad-E1B-19kD(À) or Ad-E3B(À) (Po0.05). Superior efficacy of Ad-E1B-19kD(À) over Ad-E3B(À) and Ad-E1B-19kD(À)/E3B(À) were also seen in the PT45 human pancreatic tumor xenograft model (data not shown).
Discussion
In this paper, we report data on the effects of deleting functionally redundant adenovirus antiapoptotic genes involved in resistance to TNF-a; we explored deletion of the E1B-19kD gene, the E3B gene region or both. This is the first publication on the second generation of gene deletion viruses (adenovirus or others) in which 3 , viruses or PBS were injected intravenously daily for five consecutive days, as described in the Materials and methods. The E1B-19kD(À) mutant (dl250) showed superior efficacy than wild type and other mutant viruses.
Oncolytic adenovirus E1B-19kD, E3B and E1B-19kD/E3B deletion mutants T-C Liu et al functionally redundant and interacting viral genes are deleted in isolation and in combination, and evaluated in the context of a critical apoptosis-inducing antiviral cytokine; all three permutations are compared in multiple assays, in vitro and in vivo, for both selectivity and efficacy.
In cancer cells in vitro, the Ad-E1B-19kD(À) showed enhanced viral replication, release and potency in a broad range of cancer cells regardless of TNF-a treatment; these effects were particularly evident at early time-points in the replicative cycle (eg 48 h). In normal cells, in contrast, TNF-a significantly reduced the replication of Ad-E1B-19kD(À); Adwt was unaffected. Apoptosis-associated degradation of Ad-E1B-19kD(À) DNA was suggested by a decrease in infectious units and increased caspase-3 over time. Deletion of the E3B gene region had similar effects but these were less pronounced and more delayed compared to E1B-19kD-deletion. Deletion of both gene regions in the presence of TNF-a did not result in superior selectivity compared to E1B-19kD deletion alone. Ad-E1B-19kD(À) also demonstrated clear cancer selectivity in vivo in immunocompetent tumor-bearing mice. While viral titers decreased in the livers of immunocompetent mice by 490% over 48 h relative to Adwt, intratumoral viral titers increased by 4100-fold over the same time-period. Moreover, the intratumoral spread of Ad-E1B-19kD(À) was dramatically increased versus Adwt. Finally, Ad-E1B-19kD(À) demonstrated significant antitumoral efficacy in all murine tumor models tested and was superior to Adwt. These efficacy findings were consistent between intravenous and intratumoral dosing routes. Therefore, the E1B-19kD(À) mutant is both a broadly potent and selective oncolytic adenovirus. Deletion of E3B resulted in enhanced inflammation and clearance from both normal liver and tumor tissues in vivo. These data extend previously published data on the effects of E3B gene deletion in isolation. 30, 38 The E1B-19kD(À)/E3B(À) mutant was suppressed to a greater degree in normal tissues compared to either single deletion mutant; in tumors its replication and spread was intermediate between the two single deletion mutants.
These results are novel and have important implications for the fields of virology, immunology and oncolytic adenovirus development. This is the first examination of interactions between different/potentially redundant viral genes in the context of an oncolytic adenovirus. This has been largely ignored with all therapeutic viruses, including adenoviruses such as Onyx-015. Previous publications on E1B-19kD mutants, 24, 29, 30 all of which contained deletions in E3B as well as in E1B-19kD, looked simply at efficacy. The interaction of the E3B and E1B-19kD gene products, the role of the antiviral cytokine TNF-alpha, and tumorselectivity and safety were not explored. As we show in the current paper, the (1) E3B deletion and (2) lack of TNF consideration presented in those studies substantially confounded the results. In addition to relevance for the E1B-19kD-deleted adenoviruses listed above, this novel work also has major implications for the Onyx-015 adenovirus, as well as other E1B-55kD-deleted oncolytic adenoviruses. Our report suggests that functional redundancy between E1B-55kD and other antiapoptotic and/or anti-p53 gene products may have contributed to the variable (and controversial) selectivity results reported in different systems. Our results demonstrate that these major limitations should be addressed for this entire generation of oncolytic viruses. In addition, we also demonstrated that proper manipulations of these genes can overcome two of the most difficult hurdles in adenovirus virotherapy: limited persistence and intratumoral spread.
The mechanism by which E1B-19kD-deletion results in enhanced replication in cancer cells appears to be threefold. First, cancer cells have genetic alterations (eg Bcl-2 overexpression; loss of Bax and/or p53 function) that protect them from apoptosis from intrinsic or extrinsic signals. These genetic alterations have been shown previously to substitute for E1B-19kD antiapoptotic functions. In addition, previous investigators have reported a transcriptional antagonism between E1A and E1B-19kD; E1B-19kD blocks E1A-13S-mediated NF-kappa-B activation and transcriptional enhancement.
39 E1B-19kD can also antagonize E3-ADP (adenoviral death protein) in preventing early viral release. Therefore, it appears that the replication of E1B-19kD(À) mutants is increased in cancer cells due to cancer genetics (antiapoptotic mechanisms) and viral genetics (loss of E1A/NF-kappa-B-inhibition). Further study will be necessary to determine which elements are most critical for this phenotype.
The effects of these mutants on normal primary cells had not been previously described, despite the critical role of TNF-a family members on adenovirus biology in vivo. Our study is therefore the first to report that E1B-19kD(À) mutants have reduced cytopathic effects and replication in normal cells, specifically in the presence of TNF-a in vitro. Apoptosis of E1B-19kD(À)-infected normal cells leads to degradation of infectious viruses, thereby limiting further virus spread and toxicity. Previous publications have demonstrated an anti-TNF protective effect for E1B-19kD or E3-10.4/ 14.5kD, -14.7kD (E3B region genes) in isolation. However, these studies have not reported on the roles of E1B-19kD or the E3B genes alone and in combination. Our data demonstrate that both gene regions play an important role, and that their functions appear to be partially redundant in normal primary cells in vitro in the presence of TNF-a but complementary in normal liver tissues in vivo. Of note, our previous data from clinical trials showed that cancer patients have TNF levels of 0.02-0.04 ng/ml prior Ad treatment, and 0.03-6.5 ng/ml after Ad delivery. 33, 34 Given that the adenovirus replication cycle is 48-72 h, this timeframe is appropriate to inhibit Ad replication.
In the current study, the E1A expression of the E1B-19kD(À) mutant in JC tumors was five-fold greater than that of wild type, yet the infectious PFU produced was 1800-fold greater. We believe the difference was due to the fact that the E1A score is dependent on the number and distribution of infected cells rather than on the absolute number of infectious virions produced. Therefore, although the trends in E1A and PFU are similar, the degrees of enhancement are not the same. E1A score and PFU/gm tissue are not necessarily linearly related.
In addition, the active caspase-3 levels of mutant viruses-infected NHBE cells were all high, while in vivo only the E1B-19kD(À) mutant-treated livers showed high active caspase-3 levels. There are several possible explanations. Firstly, E3B(À) mutants induced high level
of periportal inflammation, which might in turn have limited the numbers of hepatocytes infected. Since intravenously delivered virus mostly localized in the periportal area (as shown by viral gene expression analysis), the profound immune response might have limited the spread of viruses. A previous publication has shown that adenoviral mutants with deletions in part of the E3B gene region induced a significant inflammatory response in murine lung. 40 Hence, without efficient viral spread and gene expression in livers, the overall apoptosis induction would be expected to be lower than that seen in dl250-treated livers. In addition, the timeframe of induction of apoptosis by viruses in vivo could be different from that in vitro. Since caspase-3 activation happens only in a narrow window during the apoptosis process, it is possible that the time-points selected in this study did not reflect the peak caspase-3 activation process. Future studies will likely assess multiple early timepoints postinfection.
The complexity of the phenotype of cells infected with these mutants can also be explained by the multiple functions of each gene product. We and other groups have shown that E3B proteins protect against TNFinduced apoptosis in normal cells in vitro, yet E3B deletion can also enhance inflammation in normal tissues such as lung and liver, in addition to tumors. 38, 40 This can be attributed to the various functions of both E3B and TNF-a. Adenoviruses with deletions in the E3B region failed to antagonize the induction of certain chemokines, thereby potentially facilitating virus clearance. On the other hand, TNF-a can further stimulate the induction of other chemokines and cytokines, which will help clearing the viruses directly or indirectly. Thus, from this and others data, E3B appears to be critical for adenovirus persistence in vivo through different mechanisms. As E3B is often deleted in currently available oncolytic adenoviruses in clinical trials (eg Onyx-015, CV706), this might account for the low efficacy seen with these viruses as a single agent. Maintaining the E3B region intact is therefore expected to increase oncolytic adenovirus persistence in tumors.
The mechanisms of adenovirus clearance and toxicity in vivo have been subjects of intensive investigation in recent years. Although TNF-a is known to be one of the major antiadenoviral cytokines, studies have shown that depleting TNF-a alone does not completely ameliorate the toxicity and clearance of microorganisms such as human adenovirus, as the redundancy of LT-a compensates for TNF-a deletion. 41 In contrast, another group reported that the status of TNFR (both TNFR1 and TNFR2), but not the cytokines LT-a and/or TNF-a themselves, determined the toxicity and clearance of adenovirus. 42 Similar studies in mice with cytokines and cytokine receptors knocked out genetically (eg TNF, interferons) are planned and may be particularly illustrative. We predict that differences in the clearance rates of E1B-19kD-and/or E3B-deleted adenoviruses will be less pronounced or even lost completely in the absence of fully functional antiviral cytokine pathways.
In summary, our work showed that deletion of the E1B-19kD gene from adenovirus resulted in marked selectivity in the presence of TNF-a and significantly improved potency in vitro. In vivo, the E1B-19kD deletion not only reduced toxicity to normal tissue, it also enhanced viral replication and spread in tumor tissue, leading to enhanced antitumoral efficacy. E3B deletion could also enhance selectivity in the presence of TNF-a in vitro. However, this deletion was also associated with enhanced viral clearance from tumors in immunocompetent hosts in vivo, thus limiting the antitumoral efficacy. Deleting both E1B-19kD and E3B also resulted in reduced efficacy compared to E1B-19kD-deletion in isolation, but superior activity compared to E3B(À) alone. Therefore, E1B-19kD deletion enhanced the selectivity and antitumoral efficacy for an oncolytic adenovirus whereas E3B deletion was detrimental for antitumoral potency. Oncolytic adenoviruses may therefore benefit from the incorporation of an E1B-19kD deletion as well as maintaining the E3B region intact to increase both selectivity and potency. The incorporation of these two strategies can potentially overcome the two most critical limitations of oncolytic viruses: limited viral spread and rapid virus clearance. Deletion of E1B-19kD also results in additional space being available for the insertion of therapeutic transgene(s) and/or heterologous regulatory elements (eg tissue-specific promoterenhancer elements), since packaging becomes extremely inefficient once the viral genome increases by more than 5%. 7 Furthermore, redundant viral genes should be carefully examined with their biological mediators/ targets in the context of oncolytic virus to fully reveal their impact. 
Materials and methods
Cell lines and cell cultures
Viruses
The E3B-deleted adenoviral mutant dl309 and E1B-19kD-/ E3B-deleted mutant dl337 were provided by Dr T Shenk. 43, 44 Wild-type Ad5 served as control. dl250, as described before, 45 is an Ad2 background virus with an E1B-19kD deletion, and provided by Dr G Chinnadurai. Wild-type Ad2 served as a control for dl250. dl1520, provided by Dr A Berk, is an Ad5/Ad2 chimera with deletions in E1B-55kD and E3B. 46 The replication-defective Ad5 mutant dl312 43 was inactivated by psoralen-UV as previously described 31 to serve as a nonreplicating particle control for in vitro cell survival and in vivo efficacy studies. All adenoviruses were grown on the human embryonic kidney cell line HEK293 as previously described. 31 
Viral replication assays
For in vitro viral replication assays, cells were seeded in six-well plates (3 Â 105 cells/well) and infected with Oncolytic adenovirus E1B-19kD, E3B and E1B-19kD/E3B deletion mutants T-C Liu et al different viruses at 100 particles/cell (ppc) under 70-80% confluency. Experiments were repeated at least three times with each condition in triplicates. Cells were harvested and media collected 48 and 72 h postinfection (p.i.), either with or without media and cell lysate separation. For NHBE, PT45, A2780, A2780/CP and CMT-167, the samples were collected and media and cell lysate were analyzed separately. For JC, media and cells lysate were analyzed without separation. The collected samples were freeze/thawed three times, and replicating virus determined by the limiting dilution assay as described before. 25 To determine the effect of TNF-a on infected cells, NHBE, PT45, CMT-167 and JC cells were infected as described above and 6 or 24 h p.i., 0.5 ng/ml of TNF-a (Oncogene, CA, USA) was added to the cells. Samples were harvested at 48 and 72 h p.i. In vivo viral PFU recovery assays were performed as described before.
In vitro cell survival assay
For cell survival assays, 1-2 Â 10 4 cells were seeded in 96-well plates and 24 h later infected with different viruses at various concentrations. Cell survival was determined by MTS assay (Promega, CA, USA) 3-7 days p.i. and the EC 50 values of different adenoviruses were obtained as previously described. 25 All assays were performed at least three times with each condition in quadruplicate. To determine the effect of TNF-a on infected cells, cells were infected as described above and TNF-a added 6 h later (0.5 ng/ml).
In situ active caspase-3 detection
For in vitro studies, cells were grown in chamber slides 24 h before treatment. Viruses (100 ppc) and TNF-a (0.5 ng/ml) were added according to the schedule used for the viral replication assays. At various time-points p.i., slides were washed with cold PBS and fixed with methanol. The active form caspase-3 was detected by immunohistochemistry (IHC) using rabbit antiactive caspase-3 antibody (R&D system, Abingdon, UK; diluted 1:1000) and followed by the Envision TM +system (DAKO, Cambridgeshire, UK) according to the instructions of the provider. The percentages of caspase-3 positive cells were determined by counting a total of 1000 cells for each condition in triplicates. Three independent experiments were performed and the average results reported. Similar staining procedures were used to analyze in vivo samples.
Animal viral toxicity and biodistribution study
Murine lung adenocarcinoma cell line, CMT-167 cells (5 Â 10 6 cells) were injected subcutaneously into both flanks of immunocompetent C57/BL6 mice (obtained from Cancer Research UK Biological Resources, Middlesex, UK). The animals were then randomized into six treatment groups (n ¼ 9 per group): PBS, Ad5wt, dl309, dl337, Ad2wt and dl250. Intravenous (i.v.) injection of viruses was initiated once the tumor size reached 30-60 mm 3 and 1 Â 10 10 viral particles were injected via tail vein in a volume of 100 ml. At 24 and 48 h postinjection, mice were killed (three mice per time-point); tumor and liver samples were harvested. Similar studies were also carried out in immunocompetent Balb/c mice bearing JC tumors.
General histopathology
General histopathology was carried out by staining the sample slides with hematoxylin and eosin, followed by light microscopy. Cytopathic effects in liver tissues were defined as either necrosis or one of the following: enlarged nucleus, eosinophilic cytoplasm, or intranuclear inclusion bodies. The severity of the cytopathic effects was scored as follows: 1, o25% of cross section demonstrating CPE; 2, 25-49%; 3, 50-74%; 4, X75%. The extent of periportal infiltration was performed by scoring the numbers of acute inflammatory cells (neutrophils and eosinophils) surrounding the periportal area and quantitated as follows: 0, 1-3 inflammatory cells; 1, 4-10 inflammatory cells; 2, 11-15 cells; 3, 16-30 cells; 4, 430 cells.
In vivo viral gene expression IHC was used for adenoviral E1A and hexon detection in tissue samples. Samples were frozen in liquid nitrogen, sectioned and fixed with 4% formaldehyde prior to staining. These sections were first blocked with porcine serum for E1A staining and horse serum for hexon staining (DAKO, Cambridgeshire, UK; diluted 1:20), and incubated with either rabbit anti-E1A (Santa Cruz, CA, USA; diluted 1:50) or goat antihexon (Accurate Chemicals, NY, USA; diluted 1:150). After repeated washing in PBS, the biotinylated secondary antibodies (porcine antirabbit antibody for E1A, DAKO, Cambridgeshire, UK; diluted 1:300 and horse anti-goat antibody for hexon (Vector, CA, USA; diluted 1:150) were then added. The endogenous peroxidase activity was quenched with 0.3% hydrogen peroxide. The slides were incubated with streptavidin-HRP (horseradish peroxidase) complex (DAKO, Cambridgeshire, UK; diluted 1:300), followed by development in diaminobenzidine solution (DAKO, Cambridgeshire, UK) supplied with 0.03% hydrogen peroxide. Once the desired staining intensity was achieved, the slides were washed, counter-stained with hematoxylin, dehydrated, mounted an analyzed by light microscopy.
In vivo intratumoral viral replication studies
JC cells were implanted in both flanks of immunocompetent Balb/c mice. Treatment was started when tumor sizes reached 40-100 mm 3 . Intratumoral (i.t.) injections were given at days 1, 2 and 3. PBS or 1 Â 10 10 viral particles were used for each injection. At various timepoints postinjection, animals were killed and tumors harvested for analysis. Tumor tissues were weighed, homogenized, and subsequently underwent three freeze-thaw cycles prior to centrifugation and analysis of supernatants in infectious unit assays.
Efficacy studies
The antitumoral efficacy of each mutant virus compared to their relevant wild-type control virus was tested in vivo by i.v. and i.t. injection routes. For i.v. injections, MDA-MB-231 human breast carcinoma cells were implanted subcutaneously into the mammary fat pads (1 Â 10 6 cells) of ICRF C57BL/6 nu/nu mice (from Cancer Research UK Biological Resources, London, UK). Once the tumors reached 40-100 mm 3 , the mice were randomized into seven groups (n ¼ 12 per group): PBS, dl250, Ad2wt, dl309, dl337, dl1520 and Ad5wt. In total, 1 Â 10
10
Oncolytic adenovirus E1B-19kD, E3B and E1B-19kD/E3B deletion mutants T-C Liu et al viral particles were injected via tail vein for 5 consecutive days, and the animal survival was monitored. For the intratumoral injection study, PT45 human pancreatic cancer cells were implanted subcutaneously into one flank (5 Â 10 6 cells) of 6 to 8weeks old ICRF C57BL/6 nu/nu mice (from Cancer Research UK Biological Resources, London, UK). Once the tumors reached 40-100 mm 3 , the mice were randomized into six treatment groups: PBS, dl250, Ad2wt, dl309, dl337 and Ad5wt (n ¼ 12 per group). PBS or viruses were injected intratumorally at days 1, 3 and 5 at a dose of 3 Â 10 10 particles. Tumor size and animal survival were monitored and animals were killed when tumor size reached 1 cm 3 or after 3 months.
Statistical analysis
Unpaired t-test or one-way ANOVA were used for all in vitro studies and in vivo toxicity and intratumoral replication studies. Kaplan-Meier curves were compared using the log-rank test.
